Literature DB >> 22080837

LRRK2 Parkinson disease mutations enhance its microtubule association.

Lauren R Kett1, Daniela Boassa, Cherry Cheng-Ying Ho, Hardy J Rideout, Junru Hu, Masako Terada, Mark Ellisman, William T Dauer.   

Abstract

Dominant missense mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic causes of Parkinson disease (PD) and genome-wide association studies identify LRRK2 sequence variants as risk factors for sporadic PD. Intact kinase function appears critical for the toxicity of LRRK2 PD mutants, yet our understanding of how LRRK2 causes neurodegeneration remains limited. We find that most LRRK2 PD mutants abnormally enhance LRRK2 oligomerization, causing it to form filamentous structures in transfections of cell lines or primary neuronal cultures. Strikingly, ultrastructural analyses, including immuno-electron microscopy and electron microscopic tomography, demonstrate that these filaments consist of LRRK2 recruited onto part of the cellular microtubule network in a well-ordered, periodic fashion. Like LRRK2-related neurodegeneration, microtubule association requires intact kinase function and the WD40 domain, potentially linking microtubule binding and neurodegeneration. Our observations identify a novel effect of LRRK2 PD mutations and highlight a potential role for microtubules in the pathogenesis of LRRK2-related neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22080837      PMCID: PMC3263991          DOI: 10.1093/hmg/ddr526

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  33 in total

1.  Transform-based backprojection for volume reconstruction of large format electron microscope tilt series.

Authors:  Albert Lawrence; James C Bouwer; Guy Perkins; Mark H Ellisman
Journal:  J Struct Biol       Date:  2006-02-17       Impact factor: 2.867

2.  A comparative study of Lrrk2 function in primary neuronal cultures.

Authors:  Justus C Dächsel; Bahareh Behrouz; Mei Yue; Joel E Beevers; Heather L Melrose; Matthew J Farrer
Journal:  Parkinsonism Relat Disord       Date:  2010-09-17       Impact factor: 4.891

3.  Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.

Authors:  Junpeng Deng; Patrick A Lewis; Elisa Greggio; Eli Sluch; Alexandra Beilina; Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

4.  Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase.

Authors:  Katja Gotthardt; Michael Weyand; Arjan Kortholt; Peter J M Van Haastert; Alfred Wittinghofer
Journal:  EMBO J       Date:  2008-07-24       Impact factor: 11.598

5.  The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation.

Authors:  Elisa Greggio; Ibardo Zambrano; Alice Kaganovich; Alexandra Beilina; Jean-Marc Taymans; Veronique Daniëls; Patrick Lewis; Shushant Jain; Jinhui Ding; Ali Syed; Kelly J Thomas; Veerle Baekelandt; Mark R Cookson
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

6.  Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?

Authors:  Frank Gillardon
Journal:  J Neurochem       Date:  2009-06-22       Impact factor: 5.372

7.  Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.

Authors:  Edward D Plowey; Salvatore J Cherra; Yong-Jian Liu; Charleen T Chu
Journal:  J Neurochem       Date:  2008-01-07       Impact factor: 5.372

8.  Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Authors:  Byoung Dae Lee; Joo-Ho Shin; Jackalina VanKampen; Leonard Petrucelli; Andrew B West; Han Seok Ko; Yun-Il Lee; Kathleen A Maguire-Zeiss; William J Bowers; Howard J Federoff; Valina L Dawson; Ted M Dawson
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

9.  The WD40 domain is required for LRRK2 neurotoxicity.

Authors:  Nathan D Jorgensen; Yong Peng; Cherry C-Y Ho; Hardy J Rideout; Donald Petrey; Peng Liu; William T Dauer
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

10.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.

Authors:  Javier Simón-Sánchez; Claudia Schulte; Jose M Bras; Manu Sharma; J Raphael Gibbs; Daniela Berg; Coro Paisan-Ruiz; Peter Lichtner; Sonja W Scholz; Dena G Hernandez; Rejko Krüger; Monica Federoff; Christine Klein; Alison Goate; Joel Perlmutter; Michael Bonin; Michael A Nalls; Thomas Illig; Christian Gieger; Henry Houlden; Michael Steffens; Michael S Okun; Brad A Racette; Mark R Cookson; Kelly D Foote; Hubert H Fernandez; Bryan J Traynor; Stefan Schreiber; Sampath Arepalli; Ryan Zonozi; Katrina Gwinn; Marcel van der Brug; Grisel Lopez; Stephen J Chanock; Arthur Schatzkin; Yikyung Park; Albert Hollenbeck; Jianjun Gao; Xuemei Huang; Nick W Wood; Delia Lorenz; Günther Deuschl; Honglei Chen; Olaf Riess; John A Hardy; Andrew B Singleton; Thomas Gasser
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

View more
  83 in total

1.  The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm.

Authors:  A R Esteves; M G-Fernandes; D Santos; C Januário; S M Cardoso
Journal:  Mol Neurobiol       Date:  2014-11-15       Impact factor: 5.590

Review 2.  LRRK2 Pathways Leading to Neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 3.  Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs.

Authors:  Kurt R Brunden; Virginia M-Y Lee; Amos B Smith; John Q Trojanowski; Carlo Ballatore
Journal:  Neurobiol Dis       Date:  2016-12-22       Impact factor: 5.996

Review 4.  Mechanisms of LRRK2-mediated neurodegeneration.

Authors:  Elpida Tsika; Darren J Moore
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

Review 5.  Evolution of neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Biol       Date:  2012-09-11       Impact factor: 10.834

Review 6.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 7.  The association between the LRRK2 G2385R variant and the risk of Parkinson's disease: a meta-analysis based on 23 case-control studies.

Authors:  Cheng-Long Xie; Jia-Lin Pan; Wen-Wen Wang; Yu Zhang; Su-Fang Zhang; Jing Gan; Zhen-Guo Liu
Journal:  Neurol Sci       Date:  2014-07-16       Impact factor: 3.307

8.  Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.

Authors:  Gaia Skibinski; Ken Nakamura; Mark R Cookson; Steven Finkbeiner
Journal:  J Neurosci       Date:  2014-01-08       Impact factor: 6.167

Review 9.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

Review 10.  Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.

Authors:  Kurt R Brunden; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee; Carlo Ballatore
Journal:  Bioorg Med Chem       Date:  2013-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.